Ocular Therapeutix Secures $23,800,000 Series D Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c577ce67-d2a9-44b4-b1aa-2bf168d61194&Preview=1 - Date
1/28/2013 - Company Name
Ocular Therapeutix - Mailing Address
36 Crosby Dr. Bedford, MA 01730 - Company Description
Ocular Therapeutix, Inc. is a privately held company focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology and ophthalmic surgery. - Website
http://www.ocutx.com - Transaction Type
Venture Equity - Transaction Amount
$23,800,000 - Transaction Round
Series D - Proceeds Purposes
Ocular Therapeutix will use the funds to further advance development activities and implementation of clinical trials for its sustained release drug programs, including travoprost for the treatment of glaucoma, and dexamethasone for the resolution of post-operative inflammation and pain. The funds will also be used to support U.S. commercial launch efforts and to develop sustained release therapies for retinal diseases in collaboration with pharma partners. - M&A Terms
- Venture Investor
Polaris Venture Partners - Venture Investor
Versant Ventures - Venture Investor
SV Life Sciences - Venture Investor
Ascension Health Ventures
